Iduna Therapeutics

Iduna Therapeutics is a private biotechnology company and a subsidiary of Life Biosciences focused on partial epigenetic reprogramming therapies for age-related disease and tissue regeneration. The company has licensed Harvard University intellectual property covering a gene therapy system designed to express rejuvenation factors associated with induced pluripotency. Its work has been linked most directly to ocular and optic nerve applications, including preclinical research in glaucoma and age-related vision loss using AAV-delivered OSK factors. Iduna appears to function primarily as a vehicle for advancing this reprogramming platform rather than as a broadly disclosed multi-asset clinical company. Publicly available information suggests the company remains active, private, and in the preclinical stage.